Jorge Cortes, MD
Enriched profileChief of Hematology, Division of Hematology and Oncology; Deputy Director, O'Neal Comprehensive Cancer Center (also reported as Associate Director for Translation at time of hire); Professor of Medicine · University of Alabama at Birmingham (UAB)
Jorge Cortes is Chief of Hematology, Division of Hematology and Oncology; Deputy Director, O'Neal Comprehensive Cancer Center (also reported as Associate Director for Translation at time of hire); Professor of Medicine at University of Alabama at Birmingham (UAB). OpenAlex indexes 3,575 publications with 144,714 citations (h-index 180); ClinicalTrials.gov lists 67 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Jorge Cortes as a Highly Cited Researcher (Clinical Medicine, 2025).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Jorge E. Cortes is Chief of Hematology, Division of Hematology and Oncology at University of Alabama at Birmingham (UAB), Division of Hematology and Oncology / O'Neal Comprehensive Cancer Center. The public record shows 3,575 publications with 144,714 citations (h-index 180), centered on Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 64 registered clinical trials.
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Chronic Myeloid Leukemia Treatments
- 64 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 100 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 1,496.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- Clinical focus: new drug development and management of chronic and acute leukemias (CML, AML)
MDS, and myeloproliferative disorders; research contributed to approval of multiple leukemia drugs
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onealcanceruab.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 67 registered studies on ClinicalTrials.gov. The most recent:
- Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Sponsor: Ascentage Pharma Group Inc.
- Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Sponsor: Cornerstone Pharmaceuticals
Industry payments
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Otsuka Pharmaceutical Co., Ltd.Program year202512 payments$15,846openpaymentsdata.cms.gov ↗
- Novartis Pharma AGProgram year20257 payments$14,955openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year20255 payments$12,196openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%BCR-ABL tyrosine kinase inhibitors100%Scemblix100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
654 congress contributions (2004–2026) across AACR, ASCO, ASH, ESMO, SABCS per OpenAlex. The most recent:
- A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.
Blood advances
Clinical Trial2026 - CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.
Blood advances
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jorge-cortes-franco-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
augusta.elsevierpure.com/en/persons/e49e2bf3-91c6-4810-abdb-9c08d4544ee0
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →augusta.elsevierpure.com ↗ - X / Twitter
x.com/GCC_Cortes
Mentions by others
where others cite or feature them- X / Twitter
Active on X/Twitter as @GCC_Cortes (Jorge Cortes MD), posted in first person about his Blood Global Hematology editor-in-chief appointment ("I am honored to serve as editor-in-chief...") …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - Onealcanceruab.org
UAB O'Neal Comprehensive Cancer Center official announcement welcoming Dr. Jorge E. Cortes
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onealcanceruab.org ↗ - Facebook
O'Neal Cancer Center at UAB Facebook post announcing Cortes as Chief of Hematology / Deputy Director
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providerdirectory.uabmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providerdirectory.uabmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providerdirectory.uabmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providerdirectory.uabmedicine.org ↗
- Board Certified
Hematology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providerdirectory.uabmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Editor-in-Chief
Blood Global Hematology (American Society of Hematology), inaugural appointment April 2024
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hematology.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →georgiacancerinfo.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →georgiacancerinfo.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cmleukemia.com ↗
Secondary affiliations
appointments beyond the home institution- Former Director
Georgia Cancer Center, Augusta University (Sept 2019 – April 2024); Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onealcanceruab.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
- Former Deputy Chair
Department of Leukemia; Chair, AML and CML Sections; Leukemia Fellowship Program Director, The University of Texas MD Anderson Cancer Center (27 years)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →georgiacancerinfo.org ↗
Media & interviews
press, podcasts and appearances- Featured expert
"Pivotal Updates in Leukemia From ASCO 2026," Medscape (identified as Dr. Jorge Cortes of University of Alabama at Birmingham)
2026provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medscape.com ↗ - Video/podcast: "2025 Highlights of ASH with Dr. Jorge Cortes" (Oncology Brothers)
covering ASH 2025 leukemia updates
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncbrothers.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jeffrey Curtis, MD
University of Alabama at Birmingham (UAB)
Orlando Gutierrez, MD
University of Alabama at Birmingham (UAB)
Pankaj Arora, MD
University of Alabama at Birmingham (UAB)
Ashita Tolwani, MD
University of Alabama at Birmingham (UAB)